Naturalendo Tech Co., Ltd. announced that it expects to receive KRW 30 billion in funding from Nhc Limited
December 15, 2016
Share
Naturalendo Tech Co., Ltd. (KOSDAQ:A168330) announced a private placement of 10th series unregistered unguaranteed private convertible bonds for gross proceeds of KRW 30,000,000,000 on December 16, 2016. The transaction will involve participation from new investor, Nhc Limited. The bonds are issued at par and do not bear any interest. The bonds have a yield to maturity of 3% and would mature on December 20, 2021. The bonds are fully convertible into common stock of the company at a fixed conversion price of KRW 17,800 per share between the period of December 21, 2017 to November 20, 2021. The subscription and the payment date is December 20, 2016. The transaction has been approved by the board of directors of the company.
Naturalendo Tech Co.,Ltd. is a Korea-based company principally engaged in the research and development (R&D) and manufacture of hormone biotechnology products. The Company mainly provides novel phytoestrogen, which is applied in the treatment of climacteric. It also provides other hormonal formula, such as hormone disruptor inhibitor, secretagogue and inhibitor used as diet formula and growth hormone. In addition, the Company provides materials used for diet, and involves in the R&D of drug delivery systems, immune enhancer, atopy and acne, plantation factory, and others.